Management

• President and CEO - Thomas A. Krenitsky
• Vice President, General Counsel - Wayne R. Eberhardt
• Treasurer - Sylvia C. Stanat

Thomas A. Krenitsky, Ph.D. - Principal founder, President, and CEO. Dr. Krenitsky is a recognized authority on drug discovery and development. After receiving his Ph.D. in Biochemistry from Cornell University, he did a postdoctoral fellowship at Sloan-Kettering Institute for Cancer Research and then joined the research faculty at Yale Medical School. In 1966, he joined the research group of Drs. George H. Hitchings and Gertrude B. Elion at Burroughs Wellcome Co (BW Co.). Drs. Hitchings and Elion received the 1988 Nobel Prize in Medicine for the outstanding series of innovative drugs that emanated from their laboratories. Dr. Krenitsky worked directly with these outstanding scientists until their retirements. In 1983, he succeeded Dr. Elion as head of the Experimental Therapy Division and in 1989 was appointed Vice President of Research at BW Co. In this capacity, he had responsibility for over 500 professional scientists and support staff. Under his leadership, much of the development pipeline at BW Co.was discovered. In addition to drug discovery, a large part of the preclinical development functions were performed in the Research Unit at BW Co. under Dr. Krenitsky’s direction. He also played a key role in licensing activities, including assessment of drug candidates and negotiations on terms. He was a member of the BW Co. committee overseeing the clinical development of drug candidates from 1983 to 1995. Dr. Krenitsky is the author or co-author of 90 full scientific papers and 32 abstracts dealing with drug discovery. He is inventor on 30 issued US patents with more pending. He served on the Board of Directors of The Burroughs Wellcome Fund from 1990 to 1996. Dr. Krenitsky is an inventor of the drug nelarabine that is being clinically studied for T-cell malignancies and was intimately involved in the discovery and development of VALTREX®.


Wayne R. Eberhardt, Ch.E./J.D. - Vice President, Business Development, General Counsel and Secretary. Mr. Eberhardt is the former Chief Patent Counsel of Burroughs Wellcome Co, and has over 25 years experience in the chemical, pharmaceutical, and biotechnology industry. He received his law degree from St. Louis University in 1973 while employed as a patent agent by Monsanto, and was subsequently employed as a patent attorney with Johnson & Johnson from 1974 to 1989, during which time he acquired broad experience in the health care and pharmaceutical industry. As a senior attorney at Johnson & Johnson, he secured worldwide patent rights, provided infringement and validity opinions on third party patents, negotiated patent and technology licenses, served on the Board of Directors for Ethicon, and advised management on a wide variety of patent, R & D, and business issues. In 1989, he rejoined Monsanto as a senior patent attorney with responsibility for chemical and biotechnology developments in the Animal Sciences Division. In 1992, he joined Burroughs Wellcome Co as Chief Patent Counsel with responsibility for organizing its patent department, advising management in all matters relating to U.S. patents, and coordinating patent activities with the parent company in the U.K.

Sylvia C. Stanat, B.A. – Treasurer. After receiving her Bachelors degree in biology from Antioch College in Yellow Springs, Ohio, Ms. Stanat was employed as a research scientist in the CNS Division at Parke-Davis Co. She later joined the Lineberger Cancer Center at the University of NC at Chapel Hill, and then Burroughs Wellcome Co. as a research scientist in the Virology Department. She has authored and co-authored over 30 scientific papers and is an expert in mammalian cell culture. Ms. Stanat serves as a valued scientific advisor to KPI as well as its treasurer.